Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
NCT03767439 · Columbia University · PHASE2 · withdrawn · last registry update 2019-12-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Loss of funding” | – | Registry record, Columbia University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SMO within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-11-06Results posted on the registry: National Cancer Institute (NCI), 75 approved agents (NCT02788201)
- 2020-11-02Results posted on the registry: UCSF Benioff Children's Hospital Oakland, Vismodegib + Aminolevulinic acid %20 topical solution (NCT01556009)
- 2020-10-05Results posted on the registry: Sue Yom, Vismodegib (NCT01835626)
- 2020-04-15Results posted on the registry: Novartis Pharmaceuticals, LDE225 + INC424 (NCT01787552)
- 2020-03-16Phase 3 first posted: Sol-Gel Technologies, Ltd., Patidegib Topical Gel, 2% (NCT04308395)
- 2020-01-29Also stopped (terminated): Istituto Clinico Humanitas, Vismodegib (NCT02956889)
- 2020-01-22Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, LDE225-600mg + Gemcitabine (NCT01431794)
- 2019-11-15Results posted on the registry: National Cancer Institute (NCI), Vismodegib (NCT01267955)
- 2019-10-21Results posted on the registry: Eli Lilly and Company, LY2940680 Capsule(s) (Reference) + LY2940680 Tablet (Test) (NCT01681186)
- 2019-09-18Phase 3 first posted: University Hospital Heidelberg, Gemtuzumab Ozogamicin 147 + Gemtuzumab Ozogamicin 1 (NCT04093505)
- 2019-09-13Results posted on the registry: Eli Lilly and Company, Taladegib (NCT01226485)
- 2019-09-11Results posted on the registry: Eli Lilly and Company, LY2940680 (NCT01919398)
- 2019-08-14Also stopped (terminated): University of Arizona, Vismodegib + Placebo (NCT02067104)
- 2019-07-31Results posted on the registry: University of Arizona, Vismodegib + Placebo (NCT02067104)
- 2019-07-22Results posted on the registry: Eli Lilly and Company, [^14C]-LY2940680 (NCT01746745)
- 2019-07-15Results posted on the registry: PellePharm, Inc., Patidegib + Vehicle gel (NCT02762084)
- 2019-06-25Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, LDE225-600mg + Gemcitabine (NCT01431794)
- 2019-06-19Also stopped (withdrawn): Martin Gutierrez, Docetaxel + Prednisone (NCT02182622)
- 2019-05-29Results posted on the registry: Mayo Clinic, Lenalidomide + Sonidegib (NCT02086552)
- 2019-05-23Results posted on the registry: Mayo Clinic, vismodegib (150 mg PO daily) (NCT01700049)
- 2019-05-21Also stopped (terminated): Centre Leon Berard, vismodegib + Temozolomide (NCT01601184)
- 2019-04-26Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Gemcitabine, nab-Paclitaxel, GDC-0449 (NCT01088815)
- 2019-03-08Results posted on the registry: Anne Chang, Pembrolizumab + Vismodegib (NCT02690948)
- 2019-03-07Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, LDE225 (NCT02111187)
- 2019-02-28Results posted on the registry: National Cancer Institute (NCI), Goserelin Acetate + Leuprolide Acetate (NCT01163084)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision